Chemical Biology of Carbohydrates

This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

 

Carbohydrates and glycoconjugates belong to the three major classes of biopolymers. Complex carbohydrates play important roles in biological recognition processes that are represented by the presence of dense glycoconjugate layers on cells known as the glycocalyx. Despite their importance, the study of carbohydrates suffers from limited methods for their synthesis and analysis contrary to nucleic acids or proteins.

Dr Alexander Titz

“We are looking for molecules that selectively block the individual biofilm components of resistant chronic infections to restore therapeutic interventions with antibiotics.”

Alexander Titz studied chemistry at the Technical University Darmstadt and the University of Bordeaux I. His diploma thesis was prepared at Novartis Pharma AG in the Protein Structure Unit. After receiving his doctorate from the University of Basel in 2008, covering the medicinal chemistry of carbohydrate-protein interactions, he conducted post-doctoral research at the ETH Zürich (Swiss Federal Institute of Technology) at the Institute of Microbiology and Immunology. In 2010 he was awarded the Klaus-Grohe Prize for medicinal chemistry of the GDCh. Alexander Titz then moved to the Zukunftskolleg of the University of Constance as a group leader and focused on inhibitors of bacterial biofilm formation. Since 2013, he is group leader of the workgroup Chemical Biology of Carbohydrates at Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), an outpost of the HZI.

Leader

  • Dr Alexander Titz

    Alexander Titz

    Head of Junior Research Group Chemical Biology of Carbohydrates

    +49 681 98806-2500

    Contact

Bachelor & Master
Are you interested in a bachelor or master thesis? We are looking forward to your request!

Audio Podcast

  • Widerspenstige Quellen für neue Antibiotika – eine neue Strategie um Bakterien neue Wirkstoffe zu entlocken
    Sie sind winzig klein, lieben es warm und gelten unter wissenschaftlichen Insidern als neuer Stern am Antibiotikahimmel: Actinomyceten. Allerdings ist dieser Stern nicht sehr freigiebig mit seinen Produkten und wehrt sich beinahe schon zielstrebig gegen Versuche ihm neue Substanzen zu entlocken. Andriy Luzhetskyy hat einen Trick entwickelt, mit dem er die Abwehr der Actinomyceten unterwandern kann – und so neue Quellen für neuartige Antibiotika erschließt. Besuchen Sie ihn am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS)…